Full Press Release Details
Investor Webinar Presentation
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA -
9 March 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases is pleased to announce its participation in
the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 10th of March 2023 from 12:30pm AEDT/ 9:30am AWST.
Dr David Stamler - CEO will provide an overview of
the Company which is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases.
This webinar can be viewed live via Zoom and will provide
viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.
To access further details of the event and to register
at no cost, please copy and paste the following link into your internet browser:
A recorded copy of the webinar will be made available following the event.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical
stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's
lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating
patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California,
USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David
Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities
Exchange Act of 1934. The Company has tried to identify such forward- looking statements by use of such words as "expects,"
"intends," "hopes," "anticipates," "believes," "could," "may," "evidences"
and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described
in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual
Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the
Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of
the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not
historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the
Company's drug components, including, but not limited to, ATH434, uncertainties relating to the impact of the novel
coronavirus (COVID-19) pandemic on the company's business, operations and employees, the ability of the Company to procure
additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's
drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of
obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully
enforcing the Company's patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement
made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is
made. We undertake no obligation to publicly update any forward- looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.